Houston-based regenerative medicine company SpinalCyte completed the first double-blind, placebo-controlled human trial using CybroCell, a human dermal fibroblast injection to treat degenerative disc disease.
Biologics
Stempeutics Research signed an outlicensing deal with Alkem Laboratories for the knee osteoarthritis therapy Stempeucel, according to Business Today.
Bioventus extended its agreement with Seikagaku Corp. to continue distributing Supartz Fx. Under the terms of this agreement, Bioventus will be Supartz Fx's exclusive distributor in the U.S. through May 2028.
Osiris selected Jason Keefer to serve as interim president and CEO.
U.S. Stem Cell reported a 106 percent revenue increase for the third quarter of 2017, reflecting a surging demand for stem cell treatments at its clinics.
Advertisement
Orthobiologics company Royal Biologics introduced Amnio-Maxx.
Regenerative medicine company Orthocell successfully conducted a pre-clinical evaluation using CelGro collagen rope for ACL reconstruction.
Medical device company CartiHeal secured a $2.5 million investment from Bioventus, bringing the latest financing round to $21 million. The funding will go to CartiHeal's ongoing Agili-C IDE clinical study.
The first cases of Triojection, a system intended to produce ozone gas for spinal disc herniations and manufactured by Minimus Spine, were performed in Germany by Thomas Vogl, MD.
Sacramento, Calif.-based Molecular Matrix received FDA 510(k) clearance for Osteo-P, a bone graft substitute technology.